Joseph G - Search Results

1

Clinical and economic analysis of patients with acute myeloid leukemia by FLT3 status and midostaurin use at a Comprehensive Cancer Center.

Willis C, Menon J, Unni S, Au T, Yoo M, Biskupiak J, Brixner D, Ndife B, Joseph G, Bonifacio G, Stein E, Tantravahi S, Shami PJ, Kovacsovics T, Stenehjem D. Willis C, et al. Among authors: joseph g. Leuk Res. 2019 Dec;87:106262. doi: 10.1016/j.leukres.2019.106262. Epub 2019 Oct 24. Leuk Res. 2019. PMID: 31756575

2

Tyrosine kinase inhibitor therapy treatment and discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States: a clinical practice perspective.

Ritchie EK, Latremouille-Viau D, Guerin A, Pivneva I, Habucky K, Ndife B, Joseph GJ, Atallah EL. Ritchie EK, et al. Leuk Lymphoma. 2019 Jun;60(6):1476-1484. doi: 10.1080/10428194.2018.1538510. Epub 2019 Jan 22. Leuk Lymphoma. 2019. PMID: 30668234

3

Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States.

Stein E, Xie J, Duchesneau E, Bhattacharyya S, Vudumula U, Ndife B, Bonifacio G, Guerin A, Li N, Joseph G. Stein E, et al. Among authors: joseph g. Pharmacoeconomics. 2019 Feb;37(2):239-253. doi: 10.1007/s40273-018-0732-4. Pharmacoeconomics. 2019. PMID: 30382485 Clinical Trial.

4

Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations.

Stein EM, Bonifacio G, Latremouille-Viau D, Guerin A, Shi S, Gagnon-Sanschagrin P, Briggs O, Joseph GJ. Stein EM, et al. Among authors: joseph gj. J Med Econ. 2018 Jun;21(6):556-563. doi: 10.1080/13696998.2018.1425209. Epub 2018 Jan 22. J Med Econ. 2018. PMID: 29304724 Free article.

5

Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States.

Seiter K, Latremouille-Viau D, Guerin A, Ndife B, Habucky K, Tang DH, Pivneva I, Gagnon-Sanschagrin P, Joseph GJ. Seiter K, et al. Adv Ther. 2018 Oct;35(10):1671-1685. doi: 10.1007/s12325-018-0772-3. Epub 2018 Aug 28. Adv Ther. 2018. PMID: 30155792

6

Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States.

Stein EM, Yang M, Guerin A, Gao W, Galebach P, Xiang CQ, Bhattacharyya S, Bonifacio G, Joseph GJ. Stein EM, et al. Among authors: joseph gj. Health Qual Life Outcomes. 2018 Sep 21;16(1):193. doi: 10.1186/s12955-018-1013-9. Health Qual Life Outcomes. 2018. PMID: 30241538 Free PMC article.

7

Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States.

Latremouille-Viau D, Guerin A, Nitulescu R, Gagnon PS, Joseph GJ, Chen L. Latremouille-Viau D, et al. J Med Econ. 2017 Jan;20(1):63-71. doi: 10.1080/13696998.2016.1225578. Epub 2016 Sep 7. J Med Econ. 2017. PMID: 27603674 Free article.

8

Health Care Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia with Better Adherence to Tyrosine Kinase Inhibitors and Increased Molecular Monitoring Frequency.

Latremouille-Viau D, Guerin A, Gagnon-Sanschagrin P, Dea K, Cohen BG, Joseph GJ. Latremouille-Viau D, et al. Among authors: joseph gj. J Manag Care Spec Pharm. 2017 Feb;23(2):214-224. doi: 10.18553/jmcp.2017.23.2.214. J Manag Care Spec Pharm. 2017. PMID: 28125373 Free PMC article.

9

Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data.

Li N, Yang X, Fan L, Totev T, Guerin A, Chen L, Bhattacharyya S, Joseph G. Li N, et al. Among authors: joseph g. J Med Econ. 2017 Apr;20(4):328-336. doi: 10.1080/13696998.2016.1261032. Epub 2016 Dec 2. J Med Econ. 2017. PMID: 27841717 Free article.

10

Role of Cost-Sharing Subsidies on the Initiation of and Adherence to Tyrosine Kinase Inhibitor Therapy by Medicare Beneficiaries With Chronic Myeloid Leukemia.

Ritchie EK, Guerin A, Wolff J, Joseph G. Ritchie EK, et al. Among authors: joseph g. J Clin Oncol. 2017 May 20;35(15):1744-1745. doi: 10.1200/JCO.2016.72.0011. Epub 2017 Feb 13. J Clin Oncol. 2017. PMID: 28524780 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

879 results

Search Page